Start Submission Become a Reviewer

Reading: Advances in Transcatheter Aortic Valve Replacement

Download

A- A+
Alt. Display

Review Articles

Advances in Transcatheter Aortic Valve Replacement

Authors:

Neal S. Kleiman ,

Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, Texas, US
About Neal S.
M.D.
X close

Michael J. Reardon

Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, Texas, US
About Michael J.
M.D.
X close

Abstract

Transcatheter aortic valve replacement (TAVR) is becoming widely used for the treatment of symptomatic severe aortic stenosis in patients with high surgical risk. Data from The PARTNER Trial (Placement of AoRtic TraNscathetER Valves) and the Medtronic CoreValve® U.S. Pivotal Investigational Device Exemption trial indicate that survival for extreme-risk patients is superior to best medical therapy and equivalent or superior to surgical aortic valve replacement (SAVR), although long-term durability remains unknown. Paravalvular leak remains higher in TAVR than SAVR, as does permanent pacemaker implantation in self-expanding valves. New-generation valves are addressing these issues, especially for paravalvular leak. There is strong evidence that TAVR is appropriate for both extreme-risk and high-risk patients with symptomatic severe aortic stenosis, and the continued development of new valves are making implantation more reliable. This review discusses the studies supporting the use of TAVR and explores current advances in the field.

How to Cite: 1. Kleiman NS, Reardon MJ. Advances in Transcatheter Aortic Valve Replacement. Methodist DeBakey Cardiovascular Journal. 2016;12(1):33-36. DOI: http://doi.org/10.14797/mdcj-12-1-33
Published on 01 Jan 2016.
Peer Reviewed

Downloads

  • PDF (EN)